NCT04621331撤回3 期
An Open-label, Multicenter Study Investigating the Efficacy, Safety and Pharmacokinetics of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- FibroGen
- 试验地点
- 4
- 主要终点
- Proportion of patients with mean Hb ≥ 11.0 g/dL
研究概览
简要总结
This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who are receiving either hemodialysis (HD) or peritoneal dialysis (PD). The study will enroll patients between the ages of 2 to <18 years in two sequential cohorts, with the older cohort of ages 12 to <18 years enrolled first. Approximately 30 patients will be enrolled in each age-based cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically stable CKD in the opinion of the investigator.
- •Estimated glomerular filtration rate (Bedside Schwartz formula) of < 60 ml/min/1.73 m2 (stage 3, 4 and 5 CKD) for non-dialysis patients, or patients who are receiving chronic dialysis (hemodialysis or peritoneal dialysis) for ESRD.
- •For ESA-naïve patients (either NDD or DD; ESA-naïve is defined as those patients whose total duration of prior ESA exposure is ≤ 3 weeks within the preceding 12 weeks at the time informed consent is obtained), mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be < 11.0 g/dL. For patients currently receiving stable ESA dosing who will discontinue ESA and convert to roxadustat during study, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be ≥ 10.0 g/dL and ≤ 12.5 g/dL.
- •Ferritin >50 ng/mL and transferrin saturation >10% (obtained from screening visit).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2x upper limit of normal (ULN) and total bilirubin (Tbili) ≤1.5x ULN at randomization (obtained from screening visit).
- •Serum folate and vitamin B12 > LLN (obtained from screening visit).
排除标准
- •Uncontrolled hypertension as judged by the principal investigator in the 2 weeks prior to screening.
- •Known hematologic disease other than anemia associated with CKD.
- •Known malignancy within the past 5 years before screening.
- •Any prior organ transplant or any planned organ transplant during the study period.
- •Any RBC transfusion during the past 8 weeks before screening.
- •Any condition leading to significant blood loss (e.g., gastrointestinal bleeding, surgical procedures) within 8 weeks before screening or during the screening period.
- •History of chronic liver disease.
- •Pure red cell aplasia (PRCA) or history of PRCA.
- •History of epileptic seizures.
- •History of hyperlipidemia or significant thrombotic/thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).
- •History of thrombosis of an arteriovenous fistula/graft within 12 weeks prior to enrollment.
- •Any active systemic or significant infection or episode of peritonitis within 30 days of screening.
- •Any statin use within 30 days of screening.
- •Any prior exposure to roxadustat or any other HIF-PH inhibitor.
研究组 & 干预措施
Roxadustat
Experimental
Starting doses of 20, 50, 70 or 100 mg based on weight.
干预措施: Roxadustat (Drug)
结局指标
主要结局
Proportion of patients with mean Hb ≥ 11.0 g/dL
时间窗: Averaged over weeks 16-24
次要结局
- Mean change in Hb(Baseline to averaged over weeks 16-24)
- Time to first Hb response (this only applies to NDD patients)(From baseline without rescue therapy)
研究者
研究点 (4)
Loading locations...
相似试验
终止
3 期
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson DiseaseNCT05047523Alexion Pharmaceuticals, Inc.40
招募中
2 期
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMMMultiple Myeloma in RelapseNCT06255847Shanxi Bethune Hospital43
终止
2 期
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular DegenerationDry Age-related Macular DegenerationGeographic AtrophyRetinal DiseaseMacular DegenerationRetinal DegenerationNCT04643886Gemini Therapeutics, Inc.62
招募中
2 期
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusNCT06563817Beijing Tiantan Hospital53
招募中
3 期
Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentMantle Cell Lymphoma (MCL)NCT06496308Ruijin Hospital78